Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena Italy.
Department Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Expert Opin Pharmacother. 2021 Mar;22(4):415-426. doi: 10.1080/14656566.2020.1845315. Epub 2021 Jan 6.
: Schizophrenia is a very disabling condition that may result in a significant impairment of individual, professional, and social adjustments. Antipsychotics (APs), the first-line treatment for schizophrenia, in many cases modify the course of the disease, by reducing the institutionalization risk, at the price of severe and invalidating side effects. Cariprazine is one of the latest second-generation APs (SGAs) acting as a partial agonist of type 2 and 3 dopamine receptors, which was recently approved for the treatment of adult schizophrenia.: The authors provide a critical review and commentary on the currently available data on the effectiveness and tolerability of cariprazine in schizophrenic patients, with a particular focus on its specific target symptoms.: Cariprazine appears significantly effective on both acute and maintenance treatment of schizophrenia, and in improving positive, negative, and cognitive symptoms, slightly more than other SGAs. It shows a good safety and tolerability profile, with akathisia being its most common side effect. Although further independent studies are needed to clarify its precise advantages over other SGAs, cariprazine seems a promising compound not only in schizophrenia, but also in a broad range of psychiatric conditions, including perhaps bipolar and addictive disorders.
精神分裂症是一种非常致残的疾病,可能导致个人、职业和社会适应能力的严重受损。抗精神病药(APs)是精神分裂症的一线治疗药物,在许多情况下可以通过降低住院风险来改变疾病进程,但会产生严重且无效的副作用。卡利拉嗪是一种最新的第二代抗精神病药(SGAs),作为 2 型和 3 型多巴胺受体的部分激动剂,最近被批准用于治疗成人精神分裂症。
作者对卡利拉嗪在精神分裂症患者中的有效性和耐受性的现有数据进行了批判性评价和评论,特别关注其针对特定症状的疗效。
卡利拉嗪在精神分裂症的急性和维持治疗中均显示出显著疗效,并能改善阳性、阴性和认知症状,效果略优于其他 SGAs。它具有良好的安全性和耐受性,静坐不能是其最常见的副作用。尽管还需要进一步的独立研究来阐明其与其他 SGAs 相比的确切优势,但卡利拉嗪似乎是一种很有前途的化合物,不仅在精神分裂症中,而且在广泛的精神疾病中都有应用前景,包括双相情感障碍和成瘾障碍。